Abonnement à la biblothèque: Guest
Portail numérique Bibliothèque numérique eBooks Revues Références et comptes rendus Collections
Critical Reviews™ in Eukaryotic Gene Expression
Facteur d'impact: 2.156 Facteur d'impact sur 5 ans: 2.255 SJR: 0.649 SNIP: 0.599 CiteScore™: 3

ISSN Imprimer: 1045-4403
ISSN En ligne: 2162-6502

Critical Reviews™ in Eukaryotic Gene Expression

DOI: 10.1615/CritRevEukarGeneExpr.v19.i1.20
pages 47-60

Cancer Treatment-Related Bone Disease

Sue A. Brown
Department of Medicine, University of Virginia, Charlottesville, Virginia, USA
Theresa A. Guise
Division of Endocrinology, Department of Medicine, University of Texas Health Science Center at San Antonio, San Antonio, TX 78229-3900

RÉSUMÉ

Bone health may be impaired in many patients being treated for cancer. Primary tumors that reside in or form metastases to bone can result in compromised skeletal integrity. It has also been increasingly recognized that patients undergoing therapies for treatment of cancer are at higher risk of bone loss. These include androgen-deprivation therapy for prostate cancer and aromatase inhibitor therapy for breast cancer, among others. Hypogonadism induced by many of these cancer treatments results in bone loss and increases the risk of osteoporosis and fractures. Progress has been made in identifying the role of oral and intravenous bisphosphonates to prevent bone loss in these patients. This review discusses bone loss associated with cancer treatments, with a focus on breast cancer, prostate cancer, and survivors of childhood malignancies.


Articles with similar content:

Cancer Cachexia: From Molecular Mechanisms to Patient's Care
Critical Reviews™ in Oncogenesis, Vol.17, 2012, issue 3
Filippo Rossi Fanelli, Martina Esposito, Maurizio Muscaritoli, Simone Lucia
Gene Therapy in Type 1 Diabetes
Critical Reviews™ in Immunology, Vol.28, 2008, issue 4
John Iacomini, Chaorui Tian, Jesus Paez-Cortez, Jessamyn Bagley
Review of Triple Negative Breast Cancer and the Impact of Inducible Nitric Oxide Synthase on Tumor Biology and Patient Outcomes
Critical Reviews™ in Oncogenesis, Vol.21, 2016, issue 5-6
Elaine M. Walsh, Maccon M. Keane, David A. Wink, Grace Callagy, Sharon A. Glynn
Gemcitabine: A Review of Chemoresistance in Pancreatic Cancer
Critical Reviews™ in Oncogenesis, Vol.24, 2019, issue 2
Abdul Kareem Khan, Mamoon Ur Rashid, Ishtiaq Hussain, Sarfraz Ahmad, Asad Ur Rahman, Sundas Jehanzeb, Akriti Gupta Jain, Deepika Sarvepalli, Neelam Khetpal, Waqas Ullah, Badar Hasan
Gaucher Disease and Malignancy: A Model for Cancer Pathogenesis in an Inborn Error of Metabolism
Critical Reviews™ in Oncogenesis, Vol.18, 2013, issue 3
Stephan vom Dahl, Pramod K. Mistry, Barry E. Rosenbloom, Tamar Taddei